Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Antigenic variation" patented technology

Antigenic variation or antigenic alteration refers to the mechanism by which an infectious agent such as a protozoan, bacterium or virus alters the proteins or carbohydrates on its surface and thus avoids a host immune response. It is related to phase variation. Antigenic variation not only enables the pathogen to avoid the immune response in its current host, but also allows re-infection of previously infected hosts. Immunity to re-infection is based on recognition of the antigens carried by the pathogen, which are "remembered" by the acquired immune response. If the pathogen's dominant antigen can be altered, the pathogen can then evade the host's acquired immune system. Antigenic variation can occur by altering a variety of surface molecules including proteins and carbohydrates. Antigenic variation can result from gene conversion, site-specific DNA inversions, hypermutation, or recombination of sequence cassettes. The result is that even a clonal population of pathogens expresses a heterogeneous phenotype. Many of the proteins known to show antigenic or phase variation are related to virulence.

A method for detecting anti-preS1 antibody, a kit for detecting anti-preS1 antibody and application thereof

The application relates to a detection method of anti-preS1 antibody, an anti-preS1 antibody detection kit and application, the application carries out multi-sequence comparison and conservation analysis on preS1 sequences of different genotypes (A, B, C, D and CD mixed type) of HBV, takes type A (AB697487.1), type C (FJ032351.1) and type D (LC519808.1) as reference sequences, based on the sequence consistency standard of 85% of full length and 90% of the key region of functional antibody binding, a highly conservative preS1 full-length antigen sequence is systematically screened out in natural variation, the sequence can cover antigen variation of A-D type HBV, and the sequence is taken as a coating antigen to establish an indirect ELISA detection system, a good linear relationship is presented in the range of 4.88-625 ng / mL, and the Cut-off value is 33.6 ng / mL; clinical verification shows that the method can effectively distinguish chronic hepatitis B patients from healthy control groups, compared with detection methods based on partial fragments or overlapping short fragments, the false negative rate can be significantly reduced, and the method is suitable for HBV infection immune state evaluation, anti-virus curative effect monitoring and prognosis analysis.
Owner:FUDAN UNIVERSITY

Image processing method, device and electronic equipment

ActiveCN115423686BImage enhancementImage analysisClonal selectionImaging processing
The present invention provides a method, device and electronic device for image processing, wherein the method includes: obtaining a first image and a second image to be spliced; generating an antigen based on a first feature point in the first image and generating an antibody based on a second feature point in the second image; cyclically executing multiple rounds of clonal selection operations for antigen variation until the iteration ends and the global optimal antibody is determined; the first feature point of the antigen corresponding to the global optimal antibody and the second feature point corresponding to the global optimal antibody are used as alignment point pairs for alignment. The image processing method, device and electronic device provided by the embodiments of the present invention use a clonal selection algorithm to determine the alignment point pairs without the need for secondary alignment, and have good adaptability and robustness; the antigen is mutated, and the local optimal antibody determined in each round is memorized through multiple rounds of clonal selection operations, which has better adaptability and can more accurately determine the alignment point pairs to prevent local optimality.
Owner:上海电气控股集团有限公司

Methods for producing influenza HA split vaccines

A method for producing an influenza HA split vaccine is provided, wherein the vaccine produces antibodies that bind to the HA stem region of influenza, which is less likely to cause antigenic variation. The influenza HA split vaccine is subjected to an acidic treatment. By the acidic treatment, an influenza HA split vaccine is obtained, wherein the vaccine produces antibodies that bind to the LAH of the HA stem region. This influenza HA split vaccine has excellent resistance to infection by other influenza viruses with different antigenicity.
Owner:NATIONAL HEALTH CRISIS MANAGEMENT RESEARCH INSTITUTE

Method and device for constructing antigen variation prediction model and predicting influenza virus antigen variation

PendingCN119323991ABiostatisticsProteomicsAntigenic distanceMedicine
The invention relates to a method and a device for constructing an antigen variation prediction model and predicting influenza virus antigen variation. The method for constructing the antigen variation prediction model comprises the following steps: acquiring an antigen similarity score and an antigen distance of a known target virus pair; constructing a preset function based on the antigen similarity score and the antigen distance of the known target virus pair, and performing adaptive Fourier decomposition on the preset function by using a maximum selection principle to obtain an important antigen point set, an orthogonal system and an important antigen point similarity score set obtained by multiple times of maximum selection; and constructing an antigen variation prediction model based on the important antigen point set, the orthogonal system, the important antigen point similarity score set and the antigen distance of the known target virus pair. According to the method, the optimization principle and the reordering thought of adaptive Fourier decomposition are combined, the prediction model is established with less linear combinations, the method has wide applicability and data selection flexibility, and the model precision and convergence are improved.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT) +2

A class of fully human antibodies that inhibit the neuraminidase activity of H3N2 influenza virus and their applications

This invention relates to a class of fully human antibodies that inhibit the neuraminidase activity of H3N2 influenza virus and their applications, belonging to the field of biomedical technology. Addressing the shortcomings of existing technologies, such as the susceptibility of H3N2 subtypes of influenza A virus to antigenic mutations, the tendency for traditional small-molecule drugs to develop resistance, and the narrow protective spectrum of existing antibody drugs, this invention provides a class of fully human antibodies that recognize the same epitope group and inhibit the neuraminidase activity of H3N2 influenza virus. The CDR regions of these fully human antibodies exhibit high overall similarity, establishing a conserved antibody-binding backbone. Simultaneously, their heavy chain variable region CDR3 exhibits specific sequence variations, forming a structural feature of "conserved backbone + variant HCDR3". The fully human antibodies provided by this invention have low immunogenicity risk and broad application prospects in the prevention, treatment, and related diagnostic reagents and test kits for H3N2 influenza.
Owner:WESTLAKE UNIV